Prevalence of Inhibitor Development in Hemophilia A Patients Receiving Coageight: A Multicenter Cross-sectional Observational Study

Comparison of Efficacy, Safety and Costs of Recombinant FVIII Products Between On-demand and Secondary Prophylaxis Groups in Haemophilia A Patients

NCT01817868 ·Status: COMPLETED

A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A

NCT05911763 ·Status: ACTIVE_NOT_RECRUITING

Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A

NCT02035384 ·Status: COMPLETED

Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A

NCT06579144 ·Status: COMPLETED ·Phase: PHASE1

An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A

NCT01486927 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A

NCT00621673 ·Status: TERMINATED ·Phase: PHASE4

rFVIII-Fc (Produced by AryoGen Pharmed Co.) Pharmacokinetic Study

NCT06137092 ·Status: COMPLETED ·Phase: PHASE3

Prophylaxis Regimen for Hemophilia A Patients

NCT05036278 ·Status: COMPLETED ·Phase: PHASE4

Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)

NCT06003387 ·Status: RECRUITING ·Phase: PHASE3

Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A

NCT03932201 ·Status: ACTIVE_NOT_RECRUITING

A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A

NCT07226206 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A

NCT00989196 ·Status: COMPLETED ·Phase: PHASE2

Non-interventional Observation of Practical Implementation, Efficacy and Safety of Continuous Infusion With KOGENATE Bayer in Surgery

NCT00922597 ·Status: COMPLETED

A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150

NCT01625390 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia A

NCT02634723 ·Status: COMPLETED

A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A

NCT02920398 ·Status: COMPLETED ·Phase: PHASE1

A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

NCT05265286 ·Status: COMPLETED ·Phase: PHASE2

Pharmacokinetic Characterization of the Hemophilia A Population in Spain Using myPKFiT®

NCT03006965 ·Status: COMPLETED

A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B

NCT02053792 ·Status: COMPLETED ·Phase: PHASE3

Evaluation of Safety Following Immune Tolerance Induction Treatment With Turoctocog Alfa in Patients With Haemophilia A Following Inhibitor Development in NN7170-4213 Trial

NCT03588741 ·Status: TERMINATED ·Phase: PHASE3

An Observational Study to Learn More About How Well Damoctocog Alfa Pegol Works in Previously Treated Children With Hemophilia A

NCT07088458 ·Status: NOT_YET_RECRUITING

Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors

NCT02020369 ·Status: COMPLETED ·Phase: PHASE3

Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B

NCT07080905 ·Status: RECRUITING ·Phase: PHASE3

Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A

NCT01454739 ·Status: COMPLETED ·Phase: PHASE3

A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B

NCT01662531 ·Status: COMPLETED ·Phase: PHASE3